Ignite Creation Date:
2024-05-06 @ 3:46 AM
Last Modification Date:
2024-10-26 @ 11:39 AM
Study NCT ID:
NCT02379741
Status:
COMPLETED
Last Update Posted:
2017-03-27
First Post:
2015-02-16
Brief Title:
ADC-1013 First-in-Human Study
Sponsor:
Alligator Bioscience AB
Organization:
Alligator Bioscience AB
Study Overview
Official Title:
A First-in-human Multicenter Open-label Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether ADC-1013 an agonistic human monoclonal IgG1 anti-CD40 antibody is safe and tolerable when administered intratumorally as repeated injections directly into the tumor tissue or intravenously as repeated doses directly into a vein in patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None